Evolving R&D priorities and resource constraints across the globe mean clinical trials are more complex than ever. At the same time, COVID-19 has highlighted the urgent need for a more resilient and robust supply chain. Biopharma companies are heeding the call to innovate, be agile, reduce waste and, most of all, achieve patient-centricity.
Flexible solutions like demand-led supply and direct-to-patient distribution are helping sponsors address the growing list of challenges presented by today’s increasingly complex studies. The leading imperative for sponsors and their trusted vendors and suppliers alike must be patient safety, of which safeguarding the integrity of the study drugs through proper handling and keen quality oversight and ensuring continuity of supply are critical components.
This article discusses demand-led supply building blocks, creating a decentralized framework, forecasting & demand simulation, demand-led distribution, Direct-to-Patient processes, COVID-19’s impact on clinical trials and Direct-to-Patient, and the future of Direct-to-Patient.